These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15561342)

  • 1. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy.
    Knebel F; Böhm M; Staudt A; Borges AC; Tepper M; Jochmann N; Wernicke KD; Felix S; Baumann G
    Int J Cardiol; 2004 Dec; 97(3):517-20. PubMed ID: 15561342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy.
    Dandel M; Wallukat G; Englert A; Lehmkuhl HB; Knosalla C; Hetzer R
    Eur J Heart Fail; 2012 Dec; 14(12):1374-88. PubMed ID: 22892122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy.
    Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Hardt S; Goeser S; Kaya Z; Katus HA; Dengler TJ
    J Clin Apher; 2009; 24(4):141-9. PubMed ID: 19591221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy.
    Herda LR; Trimpert C; Nauke U; Landsberger M; Hummel A; Beug D; Kieback A; Dörr M; Empen K; Knebel F; Ewert R; Angelow A; Hoffmann W; Felix SB; Staudt A
    Am Heart J; 2010 May; 159(5):809-16. PubMed ID: 20435190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy.
    Staudt A; Staudt Y; Hummel A; Empen K; Dörr M; Trimpert C; Birkenmeier K; Kühl U; Noutsias M; Russ D; Felix SB
    Ther Apher Dial; 2006 Feb; 10(1):42-8. PubMed ID: 16556135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms.
    Reinthaler M; Empen K; Herda LR; Schwabe A; Rühl M; Dörr M; Felix SB
    J Clin Apher; 2015 Aug; 30(4):217-23. PubMed ID: 25346275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption.
    Staudt A; Dörr M; Staudt Y; Böhm M; Probst M; Empen K; Plötz S; Maschke HE; Hummel A; Baumann G; Felix SB
    Am Heart J; 2005 Oct; 150(4):729-36. PubMed ID: 16209975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up.
    Dörffel WV; Wallukat G; Dörffel Y; Felix SB; Baumann G
    Int J Cardiol; 2004 Dec; 97(3):529-34. PubMed ID: 15561344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study to assess the use of protein a immunoadsorption for chronic dilated cardiomyopathy.
    Cooper LT; Belohlavek M; Korinek J; Yoshifuku S; Sengupta PP; Burgstaler EA; Winters JL
    J Clin Apher; 2007; 22(4):210-4. PubMed ID: 17385721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry.
    Ohlow MA; Brunelli M; Schreiber M; Lauer B
    J Cardiol; 2017 Feb; 69(2):409-416. PubMed ID: 27890513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Outpatient medical and nurse management program in patients with chronic heart failure in a large territorial area in Piedmont. Four years of follow-up].
    Conte MR; Mainardi L; Iazzolino E; Casetta M; Asteggiano R; Lai F; Lusardi R; Sasso L
    Ital Heart J Suppl; 2005 Dec; 6(12):812-20. PubMed ID: 16444925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number of regulatory T cells correlates with hemodynamic improvement in patients with inflammatory dilated cardiomyopathy after immunoadsorption therapy.
    Bulut D; Creutzenberg G; Mügge A
    Scand J Immunol; 2013 Jan; 77(1):54-61. PubMed ID: 22998220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients.
    Harinstein ME; Berliner JI; Shah SJ; Taegtmeyer H; Gheorghiade M
    Am J Ther; 2008; 15(3):206-13. PubMed ID: 18496257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of medical therapy for heart failure on segmental myocardial function in patients with ischemic cardiomyopathy.
    Blondheim DS; Kazatsker M; Friedman Z; Lysyansky P; Meisel SR; Asif A; Smirin N; Shotan A
    Am J Cardiol; 2007 Jun; 99(12):1741-4. PubMed ID: 17560886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus.
    Dandel M; Englert A; Wallukat G; Riese A; Knosalla C; Stein J; Hetzer R
    Atheroscler Suppl; 2015 May; 18():124-33. PubMed ID: 25936316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction.
    Tehrani F; Phan A; Chien CV; Morrissey RP; Rafique AM; Schwarz ER
    Am J Cardiol; 2009 Mar; 103(6):829-33. PubMed ID: 19268740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy.
    Nagatomo Y; Baba A; Ito H; Naito K; Yoshizawa A; Kurita Y; Nakamura I; Monkawa T; Matsubara T; Wakabayashi Y; Ogawa S; Akaishi M; Yoshikawa T
    J Clin Apher; 2011; 26(1):1-8. PubMed ID: 21312253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study.
    Staudt A; Hummel A; Ruppert J; Dörr M; Trimpert C; Birkenmeier K; Krieg T; Staudt Y; Felix SB
    Am Heart J; 2006 Oct; 152(4):712.e1-6. PubMed ID: 16996843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with familial dilated cardiomyopathy on optimal heart failure therapy.
    Martins E; Cardoso JS; Campelo M; Amorim S; Moura B; Maciel MJ; Gonçalves FR
    Rev Port Cardiol; 2009 Mar; 28(3):263-8. PubMed ID: 19480309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy.
    Staudt A; Böhm M; Knebel F; Grosse Y; Bischoff C; Hummel A; Dahm JB; Borges A; Jochmann N; Wernecke KD; Wallukat G; Baumann G; Felix SB
    Circulation; 2002 Nov; 106(19):2448-53. PubMed ID: 12417541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.